Molecular Cancer Therapeutics · 2020 · 36 citations · 26 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyCancer ImmunotherapyColorectal CancerMetastatic Disease TreatmentPersonalized Cancer TherapyChemotherapy Dose-limiting ToxicityDose-limiting Toxicity AssessmentDouble-stranded Viral RnaKras-targeted TherapyOxaliplatin-based TherapyRecommended Phase Ii Dose
Abstract KRAS mutation is a negative predictive biomarker of anti-EGFR agents in patients with metastatic colorectal cancer (mCRC), and remains an elusive target. Pelareorep, a double-stranded RNA virus selectively replicates in KRAS-mutated cells, and is synergistic with irinotecan. A dose escalation trial of FOLFIRI/bevacizumab [irinotecan (150–180 mg/m2) and pelareorep (1 × 1010 TCID50–3 × 1010 TCID50)] was implemented in adult patients with oxaliplatin refractory/intolerant, KRAS-mutant mCRC. Pelareorep was administered intravenously over 1 hour on days 1–5 every 4 weeks. Additional studies included pharmacokinetics, tumor morphology, and immune responses. Among FOLFIRI-naïve patients, the highest dose of FOLFIRI/bevacizumab (180 mg/m2 irinotecan) and pelareorep (3 × 1010 TCID50) was well tolerated, without a dose-limiting toxicity. At the recommended phase II dose, 3 of 6 patients (50%) had a partial response; the median progression-free and overall survival (PFS, OS) were 65.6 weeks and 25.1 months, respectively. Toxicities included myelosuppression, fatigue, and diarrhea. Transmission electron microscopy revealed viral factories (viral collections forming vesicular structures), at various stages of development. Immunogold staining against viral capsid σ-1 protein demonstrated viral “homing” in the tumor cells. The nucleus displayed sufficient euchromatin regions suggestive of active transcription. Flow cytometry revealed rapid dendritic cell maturation (48 hours) with subsequent activation of cytotoxic T cells (7 days). The combination of pelareorep with FOLFIRI/bevacizumab is safe. The PFS and OS data are encouraging and deserve further exploration. Pelareorep leads to a clear recurrent immune stimulatory response with cytotoxic T-cell activation, and homes and replicates in the tumor.
26
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Comprehensive molecular characterization of human colon and rectal cancer
Panitumumab–FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer
Jean‐Yves Douillard, Kelly S. Oliner, Salvatore Siena et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text
Medicine, Oncology, Pharmacology +15
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer, Eric Van Cutsem, Alfredo Falcone et al. · New England Journal of Medicine · 2015 · 1.4K citations · Full text